Selective PAR-4 Antagonists for Safer Thrombosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antithrombotic therapies for thromboembolic disorders, such as warfarin and clopidogrel, have limitations including increased risk of bleeding and partial efficacy, necessitating the development of safer and more effective oral or parenteral antithrombotics.
Innovation Solution
Development of novel indole compounds as selective protease-activated receptor 4 (PAR4) antagonists to inhibit platelet aggregation, which are designed to prevent or treat thromboembolic disorders without significantly affecting hemostasis, thereby reducing the risk of bleeding complications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antithrombotic therapies (warfarin, heparin, antiplatelet agents) are used to treat thromboembolic disorders, then antithrombotic efficacy is achieved, but the risk of bleeding increases
Solution Approach 1:
The invention segments the thrombin receptor system into two distinct targets: PAR-1 and PAR-4. By developing selective PAR-4 antagonists rather than broad-spectrum anticoagulants, the therapy can specifically inhibit platelet activation through PAR-4 while preserving other hemostatic mechanisms mediated by PAR-1, thereby reducing bleeding risk while maintaining antithrombotic efficacy
Solution Approach 2:
The invention applies local quality by creating compounds with selective affinity for PAR-4 receptors over PAR-1 receptors. This selectivity allows the drug to act locally on the specific receptor subtype responsible for thrombus formation without affecting other receptors involved in normal hemostasis, thus achieving targeted therapy with reduced systemic bleeding complications
2Reliability
If PAR-1 antagonists (e.g., vorapaxar) are used to inhibit platelet aggregation, then thromboembolic events are reduced, but major bleeding complications increase
Solution Approach 1:
Instead of targeting PAR-1 as previously attempted with vorapaxar, the invention inverts the approach by selectively targeting PAR-4. This inversion is based on the understanding that PAR-4, not PAR-1, is the primary receptor mediating thrombus formation in humans. By switching targets from PAR-1 to PAR-4, the invention achieves better therapeutic outcomes with reduced bleeding risk
Solution Approach 2:
The invention changes the key parameter of receptor selectivity from PAR-1 antagonism to PAR-4 antagonism. This parameter change fundamentally alters the safety profile by selecting a receptor subtype that is more specifically involved in pathological thrombus formation rather than physiological hemostasis, thereby reducing bleeding complications while maintaining efficacy
3Reliability
If broad-spectrum anticoagulants are used to prevent thrombus formation, then thromboembolic protection is provided, but hemostatic function is impaired
Solution Approach 1:
The invention extracts the specific function of PAR-4 in thrombus formation from the broader coagulation system. By selectively blocking only PAR-4 receptors involved in platelet activation during thrombosis, the therapy removes the harmful thrombotic pathway while leaving other essential hemostatic mechanisms intact, thus providing thromboembolic protection without impairing normal hemostatic function
Data Source
AI summary
Embodiments of the invention include substituted indole compounds and compositions thereof to inhibit protease activated receptor-4. Also described are methods of preparation of compositions and methods for treating diseases related to thrombotic disorders by administration of the composition.